A quantitative immunoassay utilizing Escherichia coli cells possessing surface-expressed single chain Fv molecules

Traditional immunoassays often rely on purified antibodies, which can be costly and time-consuming to produce. Recent advances in recombinant DNA technology have enabled the expression of antibody fragments directly on microbial surfaces. This innovation allows for the use of whole cells as antibody platforms. However, the functional equivalence of surface-expressed antibodies to purified ones remains unclear. Prior work has shown that antibody fragments can be displayed on bacterial surfaces, but their binding capacity and utility in assays have not been fully established. This gap motivated the development of a new immunoassay that uses surface-expressed antibodies directly from bacterial cultures. No prior work had resolved whether these surface-expressed antibodies could function as effectively as purified ones in quantitative assays. The presence of serum proteins in immunoassays can interfere with detection, and current methods struggle to overcome this limitation. This study aimed to address these challenges by evaluating the feasibility of using surface-expressed antibodies in a functional immunoassay.

The goal was to develop and validate a new immunoassay that uses surface-expressed single chain Fv (scFv) antibody fragments on Escherichia coli cells. The study aimed to determine whether these surface-expressed antibodies could function as a ready-to-use reagent in a quantitative immunoassay. Researchers sought to assess the binding activity and density of scFv molecules on the bacterial surface. They also wanted to test whether the immunoassay could detect analytes at low concentrations. A key objective was to evaluate the immunoassay's performance in the presence of animal serum. The study aimed to compare the new method to traditional antibody-based assays in terms of speed and accuracy. Researchers also intended to explore the cost-effectiveness of producing antibody reagents using bacterial cultures. The ultimate purpose was to establish a practical and scalable immunoassay platform.

The study used Escherichia coli cells engineered to express scFv antibody fragments on their surface. Researchers performed a Scatchard analysis to measure the binding activity of these surface-expressed antibodies. They quantified the number of scFv molecules per cell using fluorescence techniques. The immunoassay process involved incubating the cells with analyte and then separating bound from unbound analyte via centrifugation. Researchers tested the assay's sensitivity by measuring detection at nanomolar concentrations. They evaluated the immunoassay's performance in the presence of animal serum to assess interference. A variety of detection methods were tested to determine compatibility with the system. The study compared the new immunoassay to conventional antibody-based methods in terms of accuracy and speed.

The Scatchard analysis showed that surface-expressed scFv antibodies retained full binding activity with a dissociation constant (Kd) of 2.2 x 10^-9 M. Each E. coli cell was found to display approximately 60,000 scFv molecules. The immunoassay detected analytes at concentrations as low as the nanomolar range. Centrifugation effectively separated bound from unbound analyte without requiring additional purification steps. The immunoassay remained functional even when animal serum was present in the sample. Multiple detection strategies were successfully applied to the system. The assay demonstrated high accuracy and reproducibility across multiple trials. The use of bacterial cultures as antibody reagents significantly reduced production costs compared to purified antibodies.

The study demonstrated that surface-expressed scFv antibodies on E. coli cells can function as a viable reagent in a quantitative immunoassay. The authors reported that these antibodies retained full binding activity and could be used in a ready-to-use format. The immunoassay's sensitivity reached the nanomolar level, making it suitable for low-concentration detection. The presence of animal serum did not interfere with the assay's performance. Researchers concluded that the immunoassay is rapid and accurate, with potential for high-throughput applications. The use of bacterial cultures simplified antibody reagent production and reduced costs. The authors proposed that this method could be adapted to various detection formats. They emphasized the practical advantages of using whole cells as antibody platforms in diagnostic assays.